Table 4.
The result of the PD 50 test of the r-HN/3A 93–143 vaccine
| Vaccine dose a | Pig | Protection b | LPBE-antibody c (dpi) | 3ABC antibody d (dpi) |
|---|---|---|---|---|
| 1 |
1501 |
yes |
1:512 |
– |
| 1503 |
yes |
1:256 |
– |
|
| 1504 |
yes |
1:128 |
– |
|
| 1528 |
yes |
1:64 |
– |
|
| 1536 |
yes |
1:256 |
– |
|
| 1/3 |
1502 |
yes |
1:128 |
– |
| 1506 |
yes |
1:32 |
– |
|
| 1529 |
yes |
1:256 |
– |
|
| 1534 |
yes |
1:64 |
– |
|
| 1533 |
yes |
1:256 |
– |
|
| 1/9 |
1505 |
yes |
1:64 |
– |
| 1507 |
yes |
1:128 |
– |
|
| 1527 |
no |
< 1:6 |
+ |
|
| 1532 |
no |
< 1:6 |
+ |
|
| 1535 |
yes |
1:512 |
– |
|
| control | 026 |
no |
< 1:6 |
+ |
| 030 | no | < 1:6 | + |
a2 μg per dose of binary ethyleimine-inactivated antigen vaccine.
bPigs were challenged by intramuscular inoculation of 1000 ID50 of r-HN.
cLPBE-antibody, liquid-phase blocking ELISA antibody. Dpi here indicates four-weeks after vaccination that LPBE-antibodies were detected.
d3ABC antibody, the antibody to the nonstructural protein 3ABC of FMDV. dpi here indicates three-weeks after challenge that 3ABC antibodies were detected. +, positive, −, negative.